Suven Life Sciences Share Price

Suven Life Scie.

CMP as on 28-Sep-21 10:16

₹ 96.15
-0.45 -0.47%

Open

₹ 97.45

Turnover (lac)

₹ 121

Prev. Close

₹ 96.60

Day's Vol (shares)

₹ 1,25,789

Day's Range (₹)

₹ 95.05
₹ 97.45

CMP as on28-Sep-21 10:16

₹ 96.05
-0.65 -0.67%

Open

₹ 96.80

Turnover (lac)

₹ 163

Prev. Close

₹ 96.70

Day's Vol (shares)

₹ 17,293

Day's Range

₹ 95.10
₹ 96.80

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 02-Aug-2021 - -
SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2021 ,inter alia, to consider and approve The Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter ended 30th June, 2021 and related matters. With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 09th August, 2021, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results of the Company under Ind AS along with review reports of the Statutory Auditors for the quarter ended 30th June, 2021. We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter ended 09th August, 2021. b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and c) A copy of the News Release of our company Update on patents during this period can be viewed at: http://suven.com/Patentupdates.aspx We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:30 P.M. (As Per BSE Announcement Dated 09.08.2021)
Board Meeting - 27-Apr-2021 - -
SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/05/2021 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Tuesday, the 04th May, 2021 at 11:30 a.m. at the Registered Office of the Company at SDE Serene Chambers, 6th Floor, Road No 5, Banjara Hills, Hyderabad-500034, to consider, among other things, inter alia, and take on record the following matter(s): To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and year ended 31st March, 2021 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April, 2021 as per PIT Code of the Company. Trading window will be opened from 7th May, 2021. You are requested to take this notice on your record. (AS Per BSE Announcement Dated on 04.05.2021)
Board Meeting - 02-Apr-2021 - -
With reference to the subject matter, we wish to inform you that in terms of the special resolution passed by the Members of the Company at its Extra-Ordinary General Meeting held on 20th March, 2021 and in accordance with the In-principle approval granted by the NSE and BSE, the Board of Directors of the Company in its meeting held today i.e. 02nd April, 2021 has allotted 1,81,00,000 (One crore eighty one lakh) Warrants convertible into Equity Shares to Jasti Property and Equity Holdings Private Limited (In its capacity as sole trustee of Jasti Family Trust), promoter group entity at an issue price of Rs. 81.57/- per Warrant on preferential basis in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.
Board Meeting - 17-Feb-2021 - -
SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/02/2021 ,inter alia, to consider and approve With reference to above subject please note that a Meeting of the Board of Directors of the Company will be held on Saturday, the 20th February, 2021 at 10:30 a.m. for considering and approving among others the proposal to issue warrants/ Equity Shares to the Promoters / Promoter Group on Preferential Basis as provided under Chapter V of the SEBI (ICDR) Regulations, 2018. The aforesaid intimation is being submitted pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended and other applicable provisions of law, we wish to inform you that the Board of Directors of the company at its meeting held today i.e. 20th February, 2021 has inter-alia considered and approved the following: 1. Issuance of 1,81,00,000 (One Crore Eighty-One Lakh) fully Convertible Warrants on Preferential Basis to the Promoter/ Promoter Group (details as annexed) of the company in accordance with the provisions of the Companies Act, 2013, Chapter V of the SEBI (lssue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable statutory provisions and subject to the approval of shareholders in the Extra-Ordinary General Meeting of the Company; (As per BSE Announcement Dated on 20/2/2021)
Board Meeting - 03-Feb-2021 - -
To consider and approve the financial results for the period ended December 31, 2020 and dividend Suven Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on February 10, 2021, declared Interim Dividend of 1.00 per equity share. (As per NSE Announcement Dated on 10/02/2021)
Board Meeting - 21-Jan-2021 - -
SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2021 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Thursday, the 28th January, 2021 at 11:30 a.m. at the Registered Office of the Company at SDE Serene Chambers, 6th Floor, Road No 5, Banjara Hills, Hyderabad-500034, to consider, among other things, inter alia, and take on record the following matter(s): To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for quarter ended 31st December, 2020 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st January, 2021 as per PIT Code of the Company. Trading window will be opened from 01st February, 2021. You are requested to take this notice on your record. With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 28th January, 2021, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results of the Company under Ind AS along with review reports of the Statutory Auditors for the quarter ended 31st December, 2020. We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter ended 31st December, 2020. b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and c) A copy of the News Release of our company Update on patents during this period can be viewed at: http://suven.com/Patentupdates.aspx We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:45 P.M. (As Per BSE Announcement dated on 28.01.2021)
Board Meeting - 20-Oct-2020 - -
SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2020 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Tuesday, the 27th October, 2020 at 11:30 a.m. at the Registered Office of the Company at SDE Serene Chambers, 6th Floor, Road No 5, Banjara Hills, Hyderabad-500034, to consider, among other things, inter alia, and take on record the following matter(s): To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter and half-year ended 30th September, 2020 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st October, 2020 as per PIT Code of the Company. Trading window will be opened from 30th October, 2020. You are requested to take this notice on your record. With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 27th October, 2020, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results of the Company under Ind AS along with review reports of the Statutory Auditors for the quarter and half-year ended 30th September, 2020. We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter and half-year ended 30th September, 2020 b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and c) A copy of the Press Release of our company We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 1:15 P.M. With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 27th October, 2020, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results of the Company under Ind AS along with review reports of the Statutory Auditors for the quarter and half-year ended 30th September, 2020. We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter and half-year ended 30th September, 2020 b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and c) A copy of the Press Release of our company (As Per BSE Announcement Dated on 27.10.2020)
Open ZERO Brokerage Demat Account